Flávia Deffert

Flávia Deffert

Auto-generated profile, based on publicly available information

Flávia Deffert

Universidade Federal do Paraná – Curitiba – Paraná – Brasil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2023 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
AJAllan Michael Junkert
Allan Michael Junkert
RAUL EDISON LUNA LAZORAUL EDISON LUNA LAZO
RAUL EDISON LUNA LAZO
FDFlávia Deffert
Flávia Deffert
Jaqueline CarneiroJaqueline Carneiro
Jaqueline Carneiro
HBHelena Hiemisch Lobo Borba
Helena Hiemisch Lobo Borba
RPRoberto Pontarolo
Roberto Pontarolo

9 July 2024 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
AVAna Paula Oliveira Vilela
Ana Paula Oliveira Vilela
FDFlávia Deffert
Flávia Deffert
RLRosa Camila Lucchetta
Rosa Camila Lucchetta
YPYara Maria da Silva Pires
Yara Maria da Silva Pires
FMFelipe Fernando Mainka
Felipe Fernando Mainka
RPRoberto Pontarolo
Roberto Pontarolo
Purpose: Pulmonary arterial hypertension (PAH) is a progressive disease with a poor prognosis, and its management should be grounded in well-developed clinical practice guidelines (CPG). Thus, we critically assess the methodological quality of the available CPG for pharmacological treatments for PAH. Methods: A systematic review (CRD42023387168) was performed in PubMed, Cochrane, Embase, and Tripdatabase (Jan-2023). Eligible records were appraised by four reviewers using the Appraisal of Guidelines, Research, and Evaluation Collaboration tool (AGREE II) and the complementary tool for assessing recommendations’ quality and certainty, AGREE REX. Descriptive statistics were used to summarize the data. Results: Overall, 31 guidelines, mainly authored by professional societies (90%), targeting only physicians as primary users (84%), were identified. Guidelines presented a moderate overall quality (scores of 63% and 51% in AGREE II and AGREE REX, respectively), with a few domains showing slight improvements over the years. AGREE II “Scope and Purpose” (94%) and “Presentation Clarity” (99%) domains obtained the highest scores. The items related to “Stakeholder involvement,” “Editorial independence,” and “Clinical applicability” (AGREE REX) were fairly reported. Conversely, CPG lacks rigor in development (32% score, AGREE II), scarcely discusses the role of stakeholders, and provides deficient data on the implementation of recommendations (scores of 35% and 46% in AGREE II and AGREE REX, respectively). No differences in the quality of guidelines published by different developers or countries were observed ( p > 0.05). Conclusion: Methodological weaknesses are common among guidelines addressing PAH treatment, especially regarding scientific rigor, stakeholders’ values and preferences, and facilitators and barriers to implementability. Particular attention should be given to developing future guidelines.

4 June 2024 in Family Practice
Verified
Journal Article
Closed access
FDFlávia Deffert
Flávia Deffert
AVAna Paula Oliveira Vilela
Ana Paula Oliveira Vilela
ACAlexandre de Fátima Cobre
Alexandre de Fátima Cobre
LFLuiz Henrique Picolo Furlan
Luiz Henrique Picolo Furlan
FTFernanda Stumpf Tonin
Fernanda Stumpf Tonin
RPRoberto Pontarolo
Roberto Pontarolo
Background: Clinical practice guidelines (CPGs) are statements to assist practitioners and stakeholders in decisions about healthcare. Low methodological quality guidelines may prejudice decision-making and negatively affect clinical outcomes in non-communicable diseases, such as cardiovascular diseases worsted by poor lipid management. We appraised the quality of CPGs on dyslipidemia management and synthesized the most updated pharmacological recommendations. Methods: A systematic review following international recommendations was performed. Searches to retrieve CPG on pharmacological treatments in adults with dyslipidaemia were conducted in PubMed, Scopus, and Trip databases. Eligible articles were assessed using AGREE II (methodological quality) and AGREE-REX (recommendation excellence) tools. Descriptive statistics were used to summarize data. The most updated guidelines (published after 2019) had their recommendations qualitatively synthesized in an exploratory analysis. Results: Overall, 66 guidelines authored by professional societies (75%) and targeting clinicians as primary users were selected. The AGREE II domains Scope and Purpose (89%) and Clarity of Presentation (97%), and the AGREE-REX item Clinical Applicability (77.0%) obtained the highest values. Conversely, guidelines were methodologically poorly performed/documented (46%) and scarcely provided data on the implementability of practical recommendations (38%). Recommendations on pharmacological treatments are overall similar, with slight differences concerning the use of supplements and the availability of drugs. Conclusion: High-quality dyslipidaemia CPG, especially outside North America and Europe, and strictly addressing evidence synthesis, appraisal, and recommendations are needed, especially to guide primary care decisions. CPG developers should consider stakeholders’ values and preferences and adapt existing statements to individual populations and healthcare systems to ensure successful implementation interventions.

18 June 2021 in Journal of Food Science and Technology
Verified
Journal Article
Closed access
PDF file
CRCintia Rompkovksi
Cintia Rompkovksi
BABruna Carla Agustini
Bruna Carla Agustini
FDFlavia Deffert
Flavia Deffert
MSMaria Goreti Amboni Stadtlober
Maria Goreti Amboni Stadtlober
DBDebora Brand
Debora Brand
TBTania Maria Bordin Bonfim
Tania Maria Bordin Bonfim

1 January 2022 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
ESEllis Marina Szabo
Ellis Marina Szabo
FDFlavia Deffert
Flavia Deffert
VBVanessa Barbosa
Vanessa Barbosa
KRKatlin Suellen Rech
Katlin Suellen Rech
IHIsabel Christina Mignoni Homem
Isabel Christina Mignoni Homem
OMObdulio Gomes Miguel
Obdulio Gomes Miguel

16 June 2017 in Acta Scientiarum. Biological Sciences
Verified
Journal Article
Open access
PDF file
FDFlávia Deffert
Flávia Deffert
BABruna Carla Agustini
Bruna Carla Agustini
GPGeraldo Picheth
Geraldo Picheth
TBTania Maria Bordin Bonfim
Tania Maria Bordin Bonfim
Fructooligosaccharides are catalyzed by β–fructofuranosidase enzyme, produced by many microorganisms. However, in order to achieve a more profitable, low time-consuming process with lower cost, researchers have sought alternatives. This study aimed to select and identify yeasts able to produce fructooligosaccharides and evaluate the influence of pH and temperature on their synthesis. Yeast suspensions, solutions of 500 g L-1 sucrose and three values of pH (4.5, 5.5, and 6.5) and temperature (40, 50, and 60ºC) were tested. Yeast species were identified by molecular techniques. Among 141 yeast isolates from grapes, 65 were able to synthesize fructooligosaccharides. The maximum concentration of fructooligosaccharides was 4.8% (w v-1), and Saccharomyces cerevisiae 222 produced 1-kestose and nystose.